Framework Code: SCF-LC-MOBP-VAL-001
System Type: Multi-Omic Diagnostic + Monitoring + Translational Validation Platform
Application: IND-Enabling • Clinical Trials • Precision Therapeutics
OBJECTIVE
To establish fully validated, multi-omic biomarker panels that:
- Quantify disease severity (drift + lock-in)
- Identify dominant SCF fault axes
- Guide PCR braid therapy selection
- Serve as primary and secondary clinical endpoints
PANEL ARCHITECTURE OVERVIEW
2.1 SCF Multi-Omic Panel Structure
Domain | Panel Code | Function |
Viral Persistence | VPP | Detect residual viral activity |
Immune | IMP | Cytokine + immune drift |
Coagulation | CMP | Microclot burden |
Metabolic | MMP | Mitochondrial function |
Neuro | NMP | Neuroimmune + autonomic |
Endothelial | EMP | Vascular integrity |
Microbiome | MbMP | Gut–immune axis |
Epigenetic | EMPG | Lock-in detection |
CORE BIOMARKER PANELS
3.1 VIRAL PERSISTENCE PANEL (VPP)
Biomarker | Method | Interpretation |
SARS-CoV-2 RNA (ddPCR) | Plasma/tissue | Active persistence |
Spike protein fragments | ELISA/MS | Residual antigen |
Subgenomic RNA | PCR | Replication competence |
Clinical Role: Curative strand targeting
3.2 IMMUNE PANEL (IMP)
Biomarker | Function | SCF Axis |
IL-6 | Inflammation driver | Immune drift |
TNF-α | Cytokine cascade | Immune drift |
IFN-γ | Viral response | Viragenesis |
CRP | Systemic inflammation | General |
Serum Amyloid A (SAA) | Amyloid formation | Clot linkage |
Composite Score: Immune Drift Index (IDI)
3.3 COAGULATION / MICRO-CLOT PANEL (CMP)
Biomarker | Method | Interpretation |
D-dimer | Plasma | Clot turnover |
Fibrin amyloid signal | ThT fluorescence | Pathological clot |
α2-antiplasmin | Proteomics | Fibrinolysis resistance |
PAI-1 | ELISA | Antifibrinolytic load |
vWF | ELISA | Endothelial activation |
Composite Score: Microclot Severity Index (MCSI)
3.4 METABOLIC PANEL (MMP)
Biomarker | Function | Interpretation |
NAD⁺ | Energy metabolism | Mitochondrial health |
Lactate | Anaerobic shift | Energy failure |
ATP (cellular assays) | Energy output | Bioenergetic collapse |
AMPK activity | Metabolic regulation | Recovery potential |
Composite Score: Bioenergetic Index (BEI)
3.5 NEURO-IMMUNE PANEL (NMP)
Biomarker | Function | Interpretation |
Neurofilament light (NfL) | Neuronal injury | Neuro damage |
IL-6 (CSF/plasma) | Neuroinflammation | CNS immune drift |
HRV (RMSSD) | Autonomic function | Vagal tone |
Cortisol rhythm | Circadian integrity | Neuroendocrine |
Composite Score: Neural Desynchronization Index (NDI)
3.6 ENDOTHELIAL PANEL (EMP)
Biomarker | Function |
ICAM-1 / VCAM-1 | Adhesion molecules |
Endothelin-1 | Vasoconstriction |
Nitric oxide (NO) | Vascular function |
Angiopoietin-2 | Vascular instability |
Composite Score: Endothelial Dysfunction Index (EDI)
3.7 MICROBIOME PANEL (MbMP)
Biomarker | Method |
Diversity index (Shannon) | 16S sequencing |
SCFA levels | Metabolomics |
Pathobiont abundance | Sequencing |
Composite Score: Microbiome Drift Index (MDI)
3.8 EPIGENETIC LOCK-IN PANEL (EMPG)
Biomarker | Method | Interpretation |
DNA methylation patterns | Bisulfite sequencing | Gene lock-in |
Histone modifications | ChIP-seq | Expression control |
miRNA signatures | qPCR | Regulatory drift |
Composite Score: Lock-In Index (LII)
INTEGRATED SCF MASTER SCORE
4.1 SCF Multi-Omic Disease Score (MODS)
MODS = f(VPP + IMP + CMP + MMP + NMP + EMP + MbMP + EMPG)
Score | Interpretation |
0–2 | Mild |
3–5 | Moderate |
6–8 | Severe |
9–10 | Systemic collapse |
CLINICAL VALIDATION DESIGN
5.1 Study Structure
Phase | Objective |
Phase I | Biomarker feasibility |
Phase II | Correlation with symptoms |
Phase III | Predictive + therapeutic response |
5.2 Cohort Stratification
- Healthy controls
- Acute COVID
- Long-COVID (mild/moderate/severe)
5.3 Validation Endpoints
Type | Endpoint |
Primary | MODS reduction |
Secondary | Symptom improvement |
Exploratory | Drift vector normalization |
LONGITUDINAL TRACKING MODEL
Timepoint | Purpose |
Baseline | Disease mapping |
Week 2–4 | Early response |
Week 8–12 | Sustained effect |
6 months | Relapse detection |
THERAPEUTIC DECISION ENGINE
7.1 Biomarker → Treatment Mapping
Dominant Index | Therapy Priority |
MCSI ↑ | Fibrinolytic + anticoagulant |
IDI ↑ | Anti-inflammatory |
BEI ↓ | Mitochondrial restoration |
NDI ↑ | Neuro-modulation |
LII ↑ | Epigenetic targeting |
SCF SYNERGY VALIDATION LINK
Each panel feeds into:
- TSSM: multi-axis persistence
- HSV-F²: metabolic efficiency
- SV-EQ: specificity
- MGIS: PK/PD alignment
- SPCI: clinical validation
REGULATORY TRANSLATION
9.1 FDA Alignment
- Biomarkers as surrogate endpoints
- IND support for:
- Mechanism of action
- Dose optimization
- Patient stratification
9.2 Companion Diagnostics
- Co-developed diagnostic panels
- Precision medicine alignment
FINAL SYSTEM INTEGRATION
Multi-Omic Panels → Drift Field → PCR Braid → Clinical Outcome
- Diagnose → Stratify → Treat → Monitor → Adapt
FINAL STATEMENT
The SCF Multi-Omic Biomarker Panel transforms Long-COVID from a symptom-defined condition into a quantifiable, mechanistically stratified disease—enabling precision, adaptive, and FDA-translatable therapeutic intervention toward a functional cure.
MASTER REGISTRY INDEX
- SCF-LC-MOBP-VAL-001 — Multi-Omic Biomarker Validation Panels
- SCF-LC-MODFM-001 — Drift Field Map
- SCF-LC-PVLI-001 — Post-Viral Lock-In Atlas
- SCF-LC-PCRB-001 — PCR Braid Strategy
- SCF-LC-CLIN-002 — Clinical Development Framework